Traws Pharma Defers Planned Phase 2a Influenza Study Of Tivoxavir Marboxil After Negative UK MHRA Review; Cash Runway Extends To Q1 2027; Advancing Alternative Influenza Antiviral Candidates

Loading news article.

Traws Pharma Defers Planned Phase 2a Influenza Study Of Tivoxavir Marboxil After Negative UK MHRA Review; Cash Runway Extends To Q1 2027; Advancing Alternative Influenza Antiviral Candidates | WAPE

Traws Pharma Defers Planned Phase 2a Influenza Study Of Tivoxavir Marboxil After Negative UK MHRA Review; Cash Runway Extends To Q1 2027; Advancing Alternative Influenza Antiviral Candidates

Article summary

Related companies

Comments —